Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

TD Cowen Maintains Buy on AstraZeneca, Raises Price Target to $95

Author: Benzinga Newsdesk | August 12, 2024 10:59am
TD Cowen analyst Steve Scala maintains AstraZeneca (NASDAQ:AZN) with a Buy and raises the price target from $90 to $95.

Posted In: AZN

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist